Evidence map›Paper›PMID 31342656›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2020

High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements in Systemic Lupus Erythematosus.

Victoria Carter, John LaCava, Martin S Taylor, Shu Ying Liang, Cecilia Mustelin, Kennedy C Ukadike, Anders Bengtsson, Christian Lood, Tomas Mustelin

Open access · bronzeAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Autoimmunity: the neoantigen hypothesis.Frontiers in immunology · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Victoria CarterUniversity of Washington, Seattle.
John LaCavaThe Rockefeller University, New York, New York, and European Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-6307-7713
Martin S TaylorMassachusetts General Hospital, Boston, and Whitehead Institute, Cambridge, Massachusetts.
Shu Ying LiangUniversity of Washington, Seattle.
Cecilia MustelinUniversity of Washington, Seattle.
Kennedy C UkadikeUniversity of Washington, Seattle.
Anders BengtssonLund University, Lund, Sweden.
Christian LoodUniversity of Washington, Seattle.
Tomas MustelinUniversity of Washington, Seattle.ORCID 0000-0001-5912-8840
University of Washington · USLund University · SEMassachusetts General Hospital · USUniversity Medical Center Groningen · NL

Funding

TR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsP41GM109824 · NIGMS · ROCKEFELLER UNIVERSITY · PI ROUT, MICHAEL P · 2014 to 2023
$18.8M
Demonstrating interactome-level connections between Alzheimer disease, LINE-1 retrotransposons, and cellular senescenceR01GM126170 · NIGMS · ROCKEFELLER UNIVERSITY · PI LACAVA, JOHN · 2018 to 2021
$2.4M
The roots of SLE: Can we cure it with a reverse transcriptase inhibitor?R21AR075134 · NIAMS · UNIVERSITY OF WASHINGTON · PI MUSTELIN, TOMAS M · 2019 to 2020
$427k
NIAMS NIH HHS R21 AR075134NIGMS NIH HHS P41 GM109824NIGMS NIH HHS R01 GM126170
6 · The paper itself

Abstract

objectiveLong interspersed nuclear element 1 (LINE-1) encodes 2 proteins, the RNA binding protein p40 and endonuclease and reverse transcriptase (open-reading frame 2p [ORF2p]), which are both required for LINE-1 to retrotranspose. In cells expressing LINE-1, these proteins assemble with LINE-1 RNA and additional RNA binding proteins, some of which are well-known autoantigens in patients with systemic lupus erythematosus (SLE). This study was undertaken to investigate whether SLE patients also produce autoantibodies against LINE-1 p40.

methodsHighly purified p40 protein was used to quantitate IgG autoantibodies in serum from 172 SLE patients and from disease controls and age-matched healthy subjects by immunoblotting and enzyme-linked immunosorbent assay (ELISA). Preparations of p40 that also contained associated proteins were analyzed by immunoblotting with patient sera.

resultsAntibodies reactive with p40 were detected in the majority of patients and many healthy controls. Their levels were higher in patients with SLE, but not those with systemic sclerosis, compared to healthy subjects (P = 0.01). Anti-p40 reactivity was higher in patients during a flare than in patients with disease in remission (P = 0.03); correlated with the SLE Disease Activity Index score (P = 0.0002), type I interferon score (P = 0.006), decrease in complement C3 level (P = 0.0001), the presence of anti-DNA antibodies (P < 0.0001) and anti-C1q antibodies (P = 0.004), and current or past history of nephritis (P = 0.02 and P = 0.003, respectively); and correlated inversely with age (r = -0.49, P < 0.0001). SLE patient sera also reacted with p40-associated proteins.

conclusionAutoantibodies reacting with LINE-1 p40 characterize a population of SLE patients with severe and active disease. These autoantibodies may represent an early immune response against LINE-1 p40 that does not yet by itself imply clinically significant autoimmunity, but may represent an early, and still reversible, step toward SLE pathogenesis.

Indexed as

Age FactorsAntibodies, AntinuclearAutoantibodiesCase-Control StudiesComplement C1qComplement C3DNA-Binding ProteinsHumansLong Interspersed Nucleotide ElementsLupus Erythematosus, SystemicLupus NephritisScleroderma, SystemicSeverity of Illness IndexAntibodies, AntinuclearAutoantibodiesComplement C1qComplement C3DNA-Binding ProteinsL1Hs-encoded protein p40, human

Identifiers

PMID31342656
PMCPMC6935427
OpenAlexW2963999797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.